Overview

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Status:
Completed
Trial end date:
2011-07-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Peficitinib